FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

The US Food and Drug Administration today approved Kisqali ribociclib in combination with an aromatase inhibitor for the treatment of preperimenopausal or postmenopausal women with hormone receptor HR-positive human epidermal growth factor receptor 2 HER2 [...]

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

Premenopausal women with hormone receptor-positive HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurr [...]

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor AI therapy in women with early-stage breast cancer1 Stiffness and join [...]

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali ribociclib in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive human epidermal growth factor receptor-2 [...]